Objective. To estimate long-term prevalence of new dysphagiarelated diagnoses in a large cohort of head and neck cancer survivors.
established. [7] [8] [9] [10] [11] [12] [13] [14] [15] However, few studies have examined swallowing outcomes more than 5 years after treatment. One of the few studies evaluating late-onset dysphagia in HNC survivors used a combination of quality-of-life assessments and videofluoroscopy, finding that 28.6% of patients reported moderate/severe choking 5 years after completing therapy and 47% of patients demonstrated aspiration on fluoroscopy a median of 67 months after completing treatment. 16 This study was limited to patients who received primary radiation therapy as treatment, had not received surgery prior to radiation, and had not received any chemotherapy, therefore providing information about only a small subset of HNC survivors.
Most available data detailing the prevalence of late-onset dysphagia are from single-institution retrospective case series. 10 Investigating dysphagia in large administrative data sets such as Surveillance, Epidemiology, and End Results (SEER)-Medicare is hampered by underreporting of the specific diagnostic code for dysphagia. 17 A few studies have established the utility of using related diagnoses as markers for dysphagia. Bhayani and colleagues 18 undertook a study of gastrostomy tube (G-tube) placement in patients with HNC and found that of 474 patients, 8 .9% continued to be G-tube dependent at 12 months and 3.9% at 24 months after radiation therapy. Similarly, Xu and colleagues 19 used the SEER database to investigate the dysphagia-related diagnosis of aspiration pneumonia in patients with HNC. Of 3513 patients, 801 developed aspiration pneumonia at a median of 5 months after the start of radiation. They found a 15.8% cumulative incidence at 1 year and 23.8% cumulative incidence at 5 years. However, as G-tube placement and aspiration pneumonia occur in a minority of patients with dysphagia, these data likely significantly underestimate the true rate of dysphagia in HNC survivors. In addition, given the limitation of SEER-Medicare data in that they are restricted to patients older than 65 years, the true prevalence of dysphagia-related diagnoses is unknown. This knowledge gap is particularly important given the increasingly younger age of HNC survivors related to an expanding population of human papillomavirus (HPV)-associated oropharyngeal cancer survivors.
Using a novel population-based cohort of HNC survivors with long-term follow-up, we investigate dysphagia and related diagnoses occurring in a delayed fashion after HNC treatment. The primary objective of the study was to determine the prevalence of new-onset dysphagia and related diagnoses occurring 5 years after treatment, as this is an area with a particular paucity of existing data. Our secondary objectives are to identify changes in rates of dysphagia-related diagnoses over varying time periods from diagnosis and to identify factors predictive of lateonset dysphagia.
Methods
Institutional review board approval was obtained for this study from the University of Utah.
Cohort Development
The Utah Population Database (UPDB) was used to establish a cohort of patients with HNC. This database links the Utah Cancer Registry, electronic medical records from the 2 largest hospital systems in Utah, statewide health care data, voter registration records, family history records, and birth and death certificates. This includes ambulatory surgery and inpatient billing data from the entire state of Utah from 1997 to 2012 as well as electronic medical records from the University of Utah Healthcare (UUHSC) and Intermountain Healthcare (IHC) , which together cover approximately 90% of Utah's population.
Cases with a diagnosis of malignancy of the oral cavity, pharynx, and larynx between 1992 and 2012 who were 18 years of age and were Utah residents at the time of diagnosis were identified, giving 3183 cases. The year 2012 was used as an end date to ensure at least 3 years of follow-up. Cases with in situ or missing stage information (n = 285), a lack of at least 3 years of follow-up time (n = 83), prior non-head and neck malignancy diagnoses (n = 451), and duplicate cases (n = 11) were excluded. To ensure adequate information about health prior to cancer diagnosis, those with a cancer diagnosis before 1996 were also excluded (n = 447) given a lack of consistent electronic medical records prior to this time. For each case, up to 5 cancer-free controls were matched based on birth year, sex, and state of birth. Those patients without adequate controls were excluded from analysis (n = 5). This gave a total of 1901 cases and 7796 matched controls for analysis. The Charlson comorbidity index (CCI) was used to quantify the prognostic comorbidity of the 2 groups. 20 Vital status, body mass index (BMI), age at the end of follow-up, and follow-up period were also compared for the 2 groups. For the survivor group staging, cancer histology, primary site, and treatment were determined.
Evaluating Late Effects
International Classification of Diseases, Ninth Revision (ICD-9) and Current Procedural Terminology (CPT) codes representing dysphagia and related diagnoses based upon a review of the medical literature were evaluated. Codes representing similar disease states were grouped together for analysis. For instance, enteral infusion of concentrated nutritional substances (ICD-9 96.6), encounter for attention to gastrostomy (ICD-9 V55.1), and gastrostomy present (ICD-9 V44.1) were all grouped under the category ''Gastrostomy Care and Use.'' For each identified code or group of codes, prevalence of new diagnosis at 0 to 2 years, 2 to 5, years and 51 years after diagnosis were determined for each dysphagia-related diagnosis for cases and controls. For calculations of prevalence of new diagnosis, patients who had received that diagnosis in a previous time period were excluded. Cumulative prevalence of each dysphagia-related diagnosis at 5 to 20 years after diagnosis was also determined, first excluding and then including patients with preexisting diagnosis prior to HNC. Similar calculations were made for our birth year, sex, and birth state matched control cohort to compare the progression of dysphagia-related diagnosis rates in a group without HNC diagnosis over time. Cox regression models were used to calculate hazard ratio based on time-to-event data as outcome variables over each time period, adjusted for BMI, CCI, and race. These hazard ratios (HRs) are also calculated in comparison to our matched cohort to control for changes in dysphagia-related diagnosis not related to HNC. To determine characteristics associated with increased risk, we also used the Cox regression model to calculate HR and 95% confidence interval (CI) for G-tube placement and any dysphagia-related diagnosis for different subgroups. Specifically, risk associated with treatment regimen, race, sex, age at diagnosis (younger than 65 years vs 65 years or older), overall stage at diagnosis, BMI (\18, 18-24.9, 25-29.9, or .30 kg/m 2 ), baseline CCI (0 vs 1 or more), cancer site, and rural vs urban setting were calculated.
Power Analysis
Sample sizes needed for power = 0.80 and a = 0.05 depend on the incidence of the late effect. For instance, with 1901 cases included, for an effect with 10% incidence, we are adequately powered to detect a relative risk of 1.3, whereas for an effect with only 1% incidence, we are powered to detect a relative risk of 3.
Results
Our cohort included 1901 HNC survivors and 7796 controls. Demographics of the cohort and control groups can be found in Table 1 . As noted above, the 2 groups were matched based on birth year and sex. The majority of both groups were born between 1930 and 1960, with the largest portion, 27.0% of cases and 27.3% of controls, born between 1940 and 1949 (P = .1949). The majority of both groups were male, 73.7% of cases and 73.3 % of controls (P = .7549). A small minority of both groups were nonwhite, but a significantly larger proportion of the controls, 8.2%, were nonwhite compared to cases, 2.9% (P \ .0001). A greater percentage of the control group was living at the end of follow-up, 83.3%, as compared to the patients with HNC, of whom only 46% were living at the end of followup (P \ .0001). Baseline BMI of the control group was significantly higher than baseline BMI of the HNC survivor group, with 64.3% of controls being overweight or obese while only 56.1% of the case group was overweight or obese (P \ .0001). The control group was noted to have a significantly higher comorbidity index compared to the survivor group (P \ .0001) at baseline. Last, the follow-up period for controls was significantly longer than that for survivors, with 70.2% of the control group being followed for more than 5 years while only 46.6% of cases were followed for more than 5 years (P \ .0001).
Details regarding cancer characteristics for our HNC survivors are found in Table 2 . Among HNC survivors, most (57.4%) were diagnosed between 50 and 69 years of age. At diagnosis, 23.4% of patients were stage I, 13.8% stage II, 14.0% stage III, 35.6% stage IV, and 13.3% had stage information missing. Most patients, 90.2%, were diagnosed with squamous histology. The most common primary site was the oropharynx (33.3%) followed closely by oral cavity (29.77%) and larynx (24.46%). The largest portion of patients (33.67%) was treated with surgery alone followed by surgery and radiation (20.88%) and radiation and chemotherapy (11.2%).
Our results demonstrated persistently elevated prevalence of new diagnosis at 0 to 2, 2 to 5, and 51 years after HNC compared to controls for all dysphagia-related diagnoses examined as detailed in Table 3 . For these calculations, any patient who had received a given diagnosis in an earlier time period was excluded from later time periods. All queried diagnoses also demonstrated increased HR for cases compared to controls across all time periods. Prevalence of new dysphagia-related diagnoses or procedures remained elevated over time in HNC survivors from 15.42% to 27.55% at 2 to 5 and 5 or more years, respectively. The HR for survivors compared to controls for receiving any dysphagia diagnosis also remained elevated at 3.21 (95% CI, 2.42-4.26) from 2 to 5 years and 2.03 (1.57-2.63) at 5 years or more. New aspiration pneumonia prevalence remained elevated in HNC survivors from 3.13% to 6.75% from 2 to 5 years to 5 or more years after diagnosis. In addition, the HR compared to controls for aspiration pneumonia remained elevated at 9.53 (5.08-17.87) from 2 to 5 years to 12.57 (7.17-22.04) at 5 or more years. Prevalence of G-tube placement procedural codes remained elevated among HNC survivors from 2.82% to 3.32% from 2 to 5 years to 5 or more years. The risk of G-tube placement remained elevated compared to controls with an HR of 51.51 (95% CI, 13.45-197.33) from 2 to 5 years and 35.22 (95% CI, 7.81-158.72) at 5 or more years from diagnosis.
We also examined cumulative prevalence of dysphagiarelated diagnoses in patients between 5 and 20 years out from treatment, including those who initially received a dysphagiarelated diagnosis in earlier time periods. Because previous studies have suggested dysphagia prior to HNC diagnosis is a risk factor for dysphagia after HNC diagnosis, we calculated this prevalence by first including and then excluding patients who had the dysphagia diagnosis prior to HNC diagnosis. 12, 16 We found 67.2% of all HNC survivors developed a dysphagia-related diagnosis at some point after HNC diagnosis while only 64.15% of HNC survivors without preexisting dysphagia before HNC developed a dysphagia-related diagnosis after HNC (P = .0518). Similarly, 14.57% of all HNC survivors developed aspiration pneumonia while 13.83% of those without preexisting diagnosis developed it after HNC (P = .3814). Last, 23.88% of all HNC survivors had a gastrostomy procedure performed at some point, while 23.46% of those without gastrostomy procedure before cancer diagnosis had this procedure at some point after cancer (P = .4673). Cumulative prevalence of all diagnoses, including diagnosis before HNC diagnosis, can be found in Table 3 .
Last, we investigated risk factors for dysphagia-related diagnoses by determining odds ratio associated with various risk factors as noted in Figure 1 . HNC survivors treated with radiation therapy had a significantly higher risk of G-tube placement more than 5 years after treatment compared to those treated with surgery alone. Both the use of radiation therapy alone and the combination of radiation and surgery demonstrated an elevated risk for G-tube placement over surgery alone (HR, 5 Age older than 65 years was associated with increased risk of being diagnosed with any dysphagia-related diagnosis or procedure more than 5 years after treatment (HR, 2.54; 95% CI, 1.75-3.69). Increasing overall stage at diagnosis was associated with increased risk of dysphagia-related diagnosis in the initial 2 years following cancer diagnosis, but this effect did not persist over time. Baseline BMI less than 18 kg/m 2 was also associated with increased risk of dysphagiarelated diagnosis more than 5 years after treatment with an 
Discussion
To our knowledge, this is the first study to look at effects of HNC and its treatment on the development of dysphagiarelated diagnoses in a large population-based cohort of both young and elderly HNC survivors. This study is unique in that it uses a population-based database with complete data for patients of all ages, as opposed to SEER-Medicare data, which are limited for patients younger than 65 years. This is particularly important given the changing demographics of HNC, with an increasing portion of diagnoses occurring in younger patients. 2 Our results demonstrated increased risk of gastrostomy with any radiation therapy. This may be confounded by an increased likelihood of receiving radiation in difficult to resect tumors and increased likelihood of receiving combined therapies in patients with more advanced disease. However, treatment with radiation alone, which is generally reserved for earlier stage cancers, was associated with more risk than combined therapy, which is used for more advanced cancers. In addition, this is consistent with existing literature, which has identified both radiation alone and combined chemotherapy and radiation as risk factors for dysphagia. 21, 22 It is not entirely clear why radiation therapy alone was associated with a higher risk than combined chemotherapy and radiation. It is possible that this difference reflects de-escalation of radiation dose in those patients who received combination therapy. However, our data set does not include information on radiation dose received; therefore, we cannot analyze this. We intend to further address this question in future work.
We noted strong correlation of dysphagia with both radiation therapy and combined chemoradiation. This is consistent with existing literature. 11, 12, [21] [22] [23] [24] Given this strong association, we would hypothesize there is likely an association between radiation toxicity and late-onset dysphagia. Hutcheson and coworkers 25 have explored the phenomenon of late radiation-associated dysphagia, which often begins more than 5 years after HNC and is associated with additional lower cranial neuropathies. 26 We noted a lower risk of dysphagia in younger patients and a higher risk of dysphagia in older patients, which is consistent with previous literature. 16 However, our cohort represents a more diverse age range than previous studies, particularly those based on Medicare data, making this finding more interesting. Further adding to the importance of these findings, in recent years, the median age of diagnosis for HNC has declined significantly. 3 Interestingly, we did not find overall stage to correlate with increased risk of dysphagia more than 2 years after treatment. Previous studies have correlated increased T stage with increased risk of long-term dysphagia. 23, 24, 27 We noted risk of dysphagia to increase with specific location within the hypopharynx, which has been previously suggested. 19 There is an ongoing question in our field as to whether prophylactic feeding tube placement may contribute to longterm dysphagia. Past studies have been mixed in their results, with some showing better long-term quality of life and shorter tube dependence without prophylactic G-tube placement and others refuting this finding. [28] [29] [30] [31] It is possible that prophylactic G-tube placement may be a complicating factor for some patients in our cohort. Unfortunately, we are unable to determine definitively from our data which G-tubes were placed prophylactically and which were placed reactively. Therefore, we are unable to control for this factor or to further contribute to the literature regarding this question.
Our study is limited in that it likely underestimates rates of dysphagia as providers frequently undercode for these diagnoses. One previous study examined all patients receiving a videofluorographic swallowing study at a single tertiary care hospital over 6 months, comparing the swallow study reports to coding associated with that admission. They found that the dysphagia code 787.2 had a sensitivity of only 22.8% with a specificity of 89.5%. 17 Another study performed chart reviews to determine whether they contained documentation for coded hospitalization complications. They found that the aspiration pneumonia code had a specificity of 91%, with 50% of cases having objective clinical evidence and 37.5% having a physician note documenting the diagnosis, but did not investigate sensitivity. 32 Furthermore, while we have a relatively large cohort, these more severe consequences occur in a very small proportion of patients, limiting statistical sensitivity as noted by our wide confidence intervals.
Conclusions
Our data suggest that new dysphagia-related diagnoses continue to occur at clinically meaningful levels in long-term HNC survivors. This has relevance with regard to initial patient counseling and treatment decisions as well as longterm HNC survivorship care. Better tools to identify patients who could benefit from long-term dysphagia management are needed.
